651 related articles for article (PubMed ID: 15018597)
1. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC; Perry CM; Faulds D
Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
[TBL] [Abstract][Full Text] [Related]
2. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
3. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A;
J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
[TBL] [Abstract][Full Text] [Related]
4. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M;
Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809
[TBL] [Abstract][Full Text] [Related]
5. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
Colwell C; Mouret P
Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Eriksson BI
Thromb Res; 2003 Jul; 109 Suppl 1():S23-9. PubMed ID: 12818631
[TBL] [Abstract][Full Text] [Related]
7. Ximelagatran in orthopaedic surgery.
Eriksson B
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():10-7. PubMed ID: 15812199
[TBL] [Abstract][Full Text] [Related]
8. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran: an orally active direct thrombin inhibitor.
Gulseth MP
Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with ximelagatran in orthopaedic surgery.
Eriksson B
Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW
J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593
[TBL] [Abstract][Full Text] [Related]
12. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
Mouret P
Hamostaseologie; 2002 Aug; 22(3):21-4. PubMed ID: 12215757
[TBL] [Abstract][Full Text] [Related]
13. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
[TBL] [Abstract][Full Text] [Related]
14. Ximelagatran--a promising new drug in thromboembolic disorders.
Petersen P
Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G;
Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978
[TBL] [Abstract][Full Text] [Related]
17. Oral direct thrombin inhibitors in clinical development.
Gustafsson D
J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871
[TBL] [Abstract][Full Text] [Related]
18. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
Rosencher N
Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973
[TBL] [Abstract][Full Text] [Related]
19. Ximelagatran.
Choudhury A; Goyal D; Lip GY
Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
[TBL] [Abstract][Full Text] [Related]
20. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
Francis CW; Davidson BL; Berkowitz SD; Lotke PA; Ginsberg JS; Lieberman JR; Webster AK; Whipple JP; Peters GR; Colwell CW
Ann Intern Med; 2002 Oct; 137(8):648-55. PubMed ID: 12379064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
